Raphael Pharmaceutical Inc. (RAPH): R&D Expense
$631.0K
Year ended 2025-12-31
$495.0K
Trailing 12 months to 2026-06-30
-18.8%
3-year compound annual growth
+6.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $631.0K | -18.7% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $776.0K | +36.4% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $569.0K | -51.7% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $1.18M | +51.8% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $776.0K | +68.3% | 2023-05-25, From 2021-01-01 |
| 2020-12-31 | $461.0K | n/a | 2022-03-30, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Raphael Pharmaceutical Inc. (RAPH) | 2025-12-31 | $631.0K | -18.7% |
| Adia Nutrition, Inc. (ADIA) | 2025-12-31 | $29.1K | n/a |
| Regencell Bioscience Holdings Ltd (RGC) | 2025-06-30 | $948.3K | -11.1% |
| Cyanotech Corp (CYAN) | 2025-03-31 | $449.0K | -34.8% |
| Mannatech Inc (MTEX) | 2025-12-31 | $800.0K | +14.3% |
| Leef Brands Inc. (LEEEF) | 2025-12-31 | $19.7K | +3.8% |
| Bon Natural Life Ltd (BON) | 2025-09-30 | $754.2K | -53.5% |
| Niagen Bioscience, Inc. (NAGE) | 2025-12-31 | $6.33M | +5.2% |
| Natural Alternatives International Inc (NAII) | 2025-06-30 | $1.80M | -5.3% |
Compare RAPH, ADIA, RGC, CYAN side by side · Screen every company in Medicinal Chemicals & Botanical Products ↗